A New England COVID-19 Registry of Patients With CNS Demyelinating Disease: A Pilot Analysis

Discussion The case fatality and hospitalization rates in our cohort were similar to those found in MS and general population COVID-19 cohorts within the region. Hospitalization was associated with increased disability, age, and comorbidities but not disease-modifying therapy use.

http://nn.neurology.org/cgi/content/short/8/5/e1046?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - August 2, 2021 Category: Neurology Authors: Money, K. M., Mahatoo, A., Samaan, S., Anand, P., Baber, U., Bailey, M., Bakshi, R., Bouley, A., Bower, A., Cahill, J., Houtchens, M., Katz, J., Lathi, E., Levit, E., Longbrake, E. E., McAdams, M., Napoli, S., Raibagkar, P., Wade, P., Sloane, J. A. Tags: COVID-19, All Demyelinating disease (CNS), Cohort studies Article Source Type: research